Tower Cold Chain introduces a pyramid, the Port of Savannah gets a new neighbor, and consumer spending negatively impacts Nestle. The post Running on Ice: Pyramids and the pharmaceutical supply chain appeared first on FreightWaves.
Eli Lilly and Company has acquired a state-of-the-art injectable medicine manufacturing facility from Nexus Pharmaceuticals LLC. The acquisition of this FDA-approved facility in Pleasant Prairie further expands Lilly’s global parenteral injectable product manufacturing network and supports increased demand for the company’s medicines.
Global Pharmaceutical Dissolution Testing Services Industry value of US$ 693.12 Million in 2023, by registering a CAGR of 8.3% By 2033
BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.71, expectations were $0.6. BioMarin Pharmaceutical Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Investments in drug research and development are paying dividends while the cost to do so stays flat, a trend that appears to be benefitting local firms. Large pharmaceutical companies’ returns on research and development investments rebounded in 2023,
WST stock results show that West Pharmaceutical Servs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires.
In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical (NASDAQ:BMRN), presenting a wide array of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts …
West Pharmaceutical (NYSE:WST) declares $0.20/share quarterly dividend, in line with previous. Forward yield 0.21% Payable Aug. 7; for shareholders of record July 31; ex-div July 31. See WST Dividend Scorecard, Yield Chart, & Dividend Growth. Why West …
(WST) on Thursday reported first-quarter net income of $115.3 million. On a per-share basis, the Exton, Pennsylvania-based company said it had net income of $1.55. Earnings, adjusted for amortization costs,
April 24, 2024 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024. “During the quarter, execution across our business led to double digit revenue growth, on a constant currency …